DAVID SAMUEL BLOCK, M.D.
Osteopathic Medicine at Wolfe St, Baltimore, MD
License number
Maryland D40651
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-1725
Personal information
See more information about DAVID SAMUEL BLOCK at radaris.comName
Address
Phone
10313 Gilmoure Dr, Silver Spring, MD 20901
Professional information
Fusion Proteins Of Natural Human Protein Fragments To Create Orderly Multimerized Immunoglobulin Fc Compositions
US Patent:
2013015, Jun 20, 2013
Filed:
Jul 28, 2011
Appl. No.:
13/812269
Inventors:
David S. Block - Baltimore MD, US
Henrik Olsen - Baltimore MD, US
Henrik Olsen - Baltimore MD, US
International Classification:
C07K 14/47
US Classification:
4241341, 5303873, 435 71, 435 696
Abstract:
The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. In comparison to the homodimeric fraction, purified multimeric stradomers have higher affinity and avidity for Fc Rs with slower dissociation and are useful in the treatment and prevention of disease. The current invention demonstrates that directly linking IgG1 Fc regions to multimerization domains leads to enhanced multimerization and biological activity.
Dr. David S Block, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
JHU INTERNAL MEDICINE
600 N Wolfe St, Baltimore 21287
(410) 955-1725 (Phone), (410) 614-9978 (Fax)
600 N Wolfe St, Baltimore 21287
(410) 955-1725 (Phone), (410) 614-9978 (Fax)
Certifications:
Internal Medicine, 1990
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
JHU INTERNAL MEDICINE
600 N Wolfe St, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
600 N Wolfe St, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1987
Perelman School of Medicine University of Pennsylvania
Graduated: 1987
David Samuel Block, Baltimore MD
Specialties:
Internist
Address:
600 N Wolfe St, Baltimore, MD 21287
Education:
University of Pennsylvania, Perelman School of Medicine - Doctor of Medicine*
Immunoglobulin Constant Region Fc Receptor Binding Agents
US Patent:
2012030, Dec 6, 2012
Filed:
May 11, 2012
Appl. No.:
13/470105
Inventors:
SCOTT E. STROME - REISTERSTOWN MD, US
DAN H. SCHULZE - BALTIMORE MD, US
DAVID S. BLOCK - RUXTON MD, US
DAN H. SCHULZE - BALTIMORE MD, US
DAVID S. BLOCK - RUXTON MD, US
Assignee:
GLIKNIK, INC. - BALTIMORE MD
UNIVERSITY OF MARYLAND, BALTIMORE - BALTIMORE MD
UNIVERSITY OF MARYLAND, BALTIMORE - BALTIMORE MD
International Classification:
C07K 16/46
US Classification:
5303873
Abstract:
IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
Methods Of Using Immunoglobulin Aggregates
US Patent:
2012012, May 17, 2012
Filed:
May 13, 2010
Appl. No.:
13/320183
Inventors:
David Block - Baltimore MD, US
Assignee:
GLIKNIK INC. - Baltimore MD
International Classification:
A61K 39/395, A61P 37/06, A61P 25/00, A61P 1/04, A61P 29/00, A61P 3/10, A61P 31/04, A61P 7/00, A61P 37/04, A61P 35/00
US Classification:
4241301
Abstract:
The current invention provides a method of treating a mammal in need of such treatment with aggregated IgG derived from pooled human plasma. The invention further provides using the discarded fraction obtained during the course of standard IgG fractionation as the source of the aggregated IgG. The methods of the invention further provide for enhancing the aggregation of the aggregate fraction as well as enriching and modifying glycoforms.
Immunoglobulin Constant Region Fc Receptor Binding Agents
US Patent:
2010023, Sep 23, 2010
Filed:
May 30, 2008
Appl. No.:
12/602609
Inventors:
Scott E. Strome - Reisterstown MD, US
Dan H. Schulze - Baltimore MD, US
David S. Block - Ruxton MD, US
Dan H. Schulze - Baltimore MD, US
David S. Block - Ruxton MD, US
Assignee:
UNIVERSITY OF MARYLAND BALTIMORE - Baltimore MD
International Classification:
A61K 9/70, C07K 16/00, A61K 39/395, G01N 33/53, C12N 5/071, C12N 5/078, A61K 9/00, A61K 9/127, A61P 35/00, A61P 31/12, A61P 31/04, A61P 31/22, A61P 33/06, A61P 37/02, A61P 25/28
US Classification:
424423, 5303871, 4241301, 435 724, 435325, 435366, 4241331, 4241341, 424443, 424429, 424427, 424450
Abstract:
IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.